SecBot SecBot
SECBOTREPLAY Home › Report › INM

INM · InMed Pharmaceuticals is conducting an at-the-market offering of up to…

InMed Pharmaceuticals Inc. · 424B5 filed Apr 3, 2026 at 16:17 ET

At the news

BEARISHIMPACT 8/10

424B5 filed Apr 3, 2026 at 16:17 ET

InMed Pharmaceuticals is conducting an at-the-market offering of up to $1.2 million in common shares through H.C. Wainwright & Co. This offering occurs amid severe financial distress, including a Nasdaq delisting notice due to low stock price and the wind down of its only revenue-generating business segment, BayMedica, due to adverse U.S. legislation. The company faces substantial doubt about its ability to continue as a going concern.

  • Company is offering up to $1,213,648 in common shares through an at-the-market offering with H.C. Wainwright & Co.
  • Stock received Nasdaq delisting notice on March 27, 2026 for failing to maintain $1.00 minimum bid price for 30 consecutive days.
  • Company is winding down BayMedica, its only revenue-generating business segment, due to H.R. 5371 legislation that will prohibit aspects of its commercial business.
  • Company has incurred significant operating losses: $3.8 million for six months ended December 31, 2025 and $8.2 million for the year ended June 30, 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access